Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer. However, resistance routinely develops in patients treated with ICIs. We conducted this retrospective study to provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiebai, Lu, Xinyuan, Zhu, Haixing, Ding, Ning, Zhang, Yong, Xu, Xiaobo, Gao, Lei, Zhou, Jian, Song, Yuanlin, Hu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910216/
https://www.ncbi.nlm.nih.gov/pubmed/36776868
http://dx.doi.org/10.3389/fimmu.2023.1089026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910216/
https://www.ncbi.nlm.nih.gov/pubmed/36776868
http://dx.doi.org/10.3389/fimmu.2023.1089026

Ejemplares similares